

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/600,364	06/21/2003	Iris Ginron Zhao	7109		
75	90 06/12/2006		EXAMINER		
Dr. Iris G. Zhao			EPPS FORD, JANET L		
1925 Chestnut S # C-20	otreet		ART UNIT	PAPER NUMBER	
Philadelphia, P.	Philadelphia, PA 19103			1633	
			DATE MAILED: 06/12/2006		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)	
Off	10/600,364	ZHAO, IRIS GINRON	
Office Action Summary	Examiner	Art Unit	
	Janet L. Epps-Ford	1633	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION  16(a). In no event, however, may a reply be tim  till apply and will expire SIX (6) MONTHS from  cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D. (35 U.S.C. 8 133)	
Status			
Responsive to communication(s) filed on <u>21 Ju</u> This action is <b>FINAL</b> . 2b)⊠ This     Since this application is in condition for allowants.	action is non-final.	osecution as to the merits is	
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	i3 O.G. 213.	
Disposition of Claims			
<ul> <li>4) Claim(s) 1-16 is/are pending in the application.</li> <li>4a) Of the above claim(s) is/are withdraw</li> <li>5) Claim(s) is/are allowed.</li> <li>6) Claim(s) is/are rejected.</li> <li>7) Claim(s) is/are objected to.</li> <li>8) Claim(s) 1-16 are subject to restriction and/or expressions.</li> </ul>			
Application Papers		•	
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the construction of the construct	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). sected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s)    Notice of References Cited (PTO-892)   Notice of Draftsperson's Patent Drawing Review (PTO-948)   Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)   Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P. 6) Other:		

## **DETAILED ACTION**

## Election/Restrictions

The inventions are distinct, each from the other because of the following reasons:

- 1. This application contains claims directed to the following patentably distinct species:
  - a. Claim 7 recites a plurality of patentably distinct artificial graft materials: specifically comprising fibrin, collagen, trunk cell, stem cell, umbilical cell, pericyte, endothelium, epithelium, embryo, clone, body fluid composition, or a combination thereof. The graft materials are patentably distinct for example; the stem cells recited in this group, represent a class of cells that express a precise array of molecular signals that control the specific developmental pathway of these cells. The trunk cell, umbilical cell, pericyte cells are distinct since they represent a distinct set of tissue types that are not disclosed as being capable of use together. The embryo included in this group is a multicellular organism, and is structurally and chemically distinct from all other members of the claimed Furthermore, the fibrin, collagen, and the body fluid composition members of this group are drawn to non-cellular components and are structurally and chemically distinct from each other, and distinct from the other members of the claimed genus. The search for one species of this group is not coextensive with any other member of the claimed group.
  - b. Claim 8 also recites a plurality of components that are comprised within the claimed artificial graft. The variety of components recited in claim 8 are

Art Unit: 1633

chemically and structurally distinct compounds, wherein the search of each component requires a separate and non-coextensive search and separate consideration of the prior art.

- c. Claims 9-13 recite a plurality of patentably distinct removable devices further comprised within the claimed artificial graft system of claim 1. Each class of removal device is directed to a product that is functionally distinct and capable of separate use in comparison to the other members of the claimed genus recited in the claim. For example, the laser included in this group has a distinct function in comparison to the needle, balloon, and ice also included in the same group.
- 2. Because these species are structurally distinct for the reasons given above, and because a search of one species does not necessarily overlap with that of another species, it would be unduly burdensome for the examiner to search and examine all of the subject matter being sought in the presently pending claims, and thus, restriction of the claimed species for examination purposes as indicated is proper.
- 3. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1-6, and 14-16 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Art Unit: 1633

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

Art Unit: 1633

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet L. Epps-Ford whose telephone number is 571-272-0757. The examiner can normally be reached on M-F, 10:00 AM through 6:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave T. Nguyen can be reached on 571-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit 1633

JLE